RxDoctor Payments Data

Devin Carey, MD

Family Medicine · Shavertown, PANPI 1366822504

Payments from drug & device makers

$12,835in general payments, 2019–2025

Across 750 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Amgen$2K
  • Lilly USA, LLC$1K
  • Pfizer$847
  • AstraZeneca$821
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$12,804100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,835 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$232,678
Medicare patients
538
Services billed
5,107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide140$158,868
EliquisApixaban188$139,378
Trelegy ElliptaFluticasone/Umeclidin/Vilanter134$99,567
JardianceEmpagliflozin82$84,694
Repatha SureclickEvolocumab78$42,355
XareltoRivaroxaban49$32,974
MounjaroTirzepatide32$31,767
TrulicityDulaglutide34$31,331
FarxigaDapagliflozin Propanediol35$31,322
JanuviaSitagliptin Phosphate28$30,941
ViberziEluxadoline14$27,484
RybelsusSemaglutide12$14,558
TradjentaLinagliptin17$11,462
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$9,993
SynthroidLevothyroxine Sodium141$7,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,696$173,426152 claims
PfizerEliquis$847$139,378188 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$673$118,043176 claims
Boehringer IngelheimJardiance, Tradjenta$796$96,15699 claims
Lilly USA, LLCMounjaro, Trulicity$1,024$63,09866 claims
AstraZenecaFarxiga, Symbicort, Nexium$821$39,95362 claims
AbbVieViberzi, Synthroid$1,979$35,214155 claims
Johnson & JohnsonXarelto$41$32,97449 claims
MerckJanuvia$67$30,94128 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$21$6,70212 claims
NovartisDiovan$103$4,20614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Shavertown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →